Previous close | 4.1000 |
Open | 4.2900 |
Bid | 4.0000 |
Ask | 4.2000 |
Strike | 105.00 |
Expiry date | 2024-09-20 |
Day's range | 3.5000 - 4.2900 |
Contract range | N/A |
Volume | |
Open interest | 2.68k |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.